Ticker Details
4D Molecular Therapeutics, Inc.
IPO Date:	December 11, 2020
Sector:	Healthcare
Industry:	Biotech
Market Cap:	$673.84M
Activated in VL:	True

Average Daily Range
Avg Daily Range:	$0.64 | 3.89%
Avg Daily Range (30 D):	$0.45 | 4.48%
Avg Daily Range (90 D):	$0.36 | 3.69%

Institutional Daily Volume
Avg Daily Volume:	.47M
Avg Daily Volume (30 D):	.83M
Avg Daily Volume (90 D):	.68M

Trade Size
Avg Trade Size (Sh.):	75
Avg Trade Size (Sh.) (30 D):	73
Avg Trade Size (Sh.) (90 D):	68

Institutional Trades
Total Institutional Trades:	1,252
Avg Institutional Trade:	$1.8M
Avg Institutional Trade (30 D):	$2.78M
Avg Institutional Trade (90 D):	$1.79M
Avg Institutional Trade Volume:	.12M
Avg Institutional Trades (Per Day):	1

Market Closing Trades
Avg Closing Trade:	$1.73M
Avg Closing Trade (30 D):	$1.91M
Avg Closing Trade (90 D):	$1.33M
Avg Closing Volume:	107.54K

News

Jun 29, 2026 @ 12:00 PM 4DMT Secures Strategic Credit Facility for up to $... Source: Na

Jun 18, 2026 @ 5:00 PM Age-related Macular Degeneration Clinical Trial Pi... Source: Delveinsight

Feb 19, 2026 @ 1:00 PM 4DMT to Participate in Upcoming Investor Conferenc... Source: Na

Nov 17, 2025 @ 11:00 AM 4DMT Appoints Kristian Humer as Chief Financial Of... Source: 4D Molecular Therapeutics

Oct 31, 2025 @ 3:02 AM 4DMT Announces Exclusive License Agreement with Ot... Source: 4D Molecular Therapeutics

Financials
	TTM	Q1 2026	Q4 2025
Basic EPS	$-2.57	$-1.01	$.43
Diluted EPS	$-2.57	$-1.01	$.43
Revenue	$88.24M	$3.05M	$85.09M
Gross Profit
Net Income / Loss	$-160.9M	$-68.76M	$19.4M
Operating Income / Loss	$-179.55M	$-73.62M	$14.72M
Cost of Revenue
Net Cash Flow	$-76.85M	$12.25M	$11.69M
PE Ratio